Trial Profile
Safety of House Dust Mite Synthetic Peptide Immuno-Regulatory Epitopes in Patients with House Dust Mite Allergy and Controlled Asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Aug 2015
Price :
$35
*
At a glance
- Drugs HDM SPIRE (Primary)
- Indications Allergic asthma; Allergic rhinoconjunctivitis
- Focus Adverse reactions
- 05 Aug 2015 New trial record